XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. Having a test that requires less reagents and resources, such as the RNA extraction kits, increases capabilities for increased testing.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

The Pharma Data

JANUARY 22, 2021

Next on the agenda: speeding up the nation’s vaccine rollout. To help do so, he’s directed the Federal Emergency Management Agency to begin constructing federally supported community vaccination centers, with the goal of having 100 centers in operation within the next month, The New York Times reported.

Vaccination 52

Vaccination Vaccine Antibody Reagent 52

The Pharma Data

MARCH 16, 2022

2 subvariant is steadily increasing in prevalence, specifically in Denmark Use of these tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines and public health interventions All Roche SARS-Cov-2 tests correctly identify the virus including these new subvariants. 3 and Delta. “In

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

DECEMBER 30, 2020

“Even with the roll-out of vaccines, the need for fast, accurate, high-volume COVID-19 testing will continue for the foreseeable future,” said Dr. Sarj Patel, President of FYR. Adding FYR as a primary testing resource will keep test processing within Montana and alleviate pressure on the state laboratory in Helena.

Reagent 52

Reagent Life Science Development Vaccination 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Used in the COVID-19 vaccines, LNPs have shown a promising track record of protecting the mRNA cargo from degradation.

Bioassay 130

Bioassay Development RNA Drugs 130

The Pharma Data

MAY 15, 2023

Before joining Solvias Group, Karen held various senior leadership roles at Novartis, including global head investor relations from 2000 to 2006, head M&A and Executive Committee member, as well as site head for the Vaccines & Diagnostics division between 2006 and 2011.

Sales 40

Sales Production Doctors Doctor 40

Roots Analysis

FEBRUARY 13, 2023

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

MARCH 20, 2021

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. delays where reagents are in. effective SARS-CoV-2 vaccine continues to attract. In the examples below, we. highlight the experiences of. The MANTIS. short supply.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Drug Discovery World

JANUARY 19, 2023

pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines. Plasmid DNA: a critical reagent pDNA is the starting material for the development of many cell and gene therapy products, irrespective of the mode of action. billion by 2030 (BioSpace, 11 August 2022).

DNA 52

DNA Manufacturing Gene Therapy Gene 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Horizon Discovery Group – U.K.-based for its cGMP-compliant CHOSOURCE platform.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. This is also expected to provide greater flexibility for potential distribution partners.

Genetics 52

Genetics Reagent Biobanking Production 52

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. BioNTech – Germany’s BioNTech and partner Pfizer secured authorization from the European Medicines Agency for its COVID-19 vaccine. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52

Roots Analysis

OCTOBER 16, 2023

Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning. Several biopharmaceutical players have collaborated and contributed to the research and development of different products, such as DNA cloning kits, vaccines and treatment solutions to combat COVID 19.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

OCTOBER 12, 2022

Furthermore, the sensitivity of the fluorescent label was shown to be around x100 greater than 2-aminobenzamide, a reagent that has been used extensively in the past to label glycans. . An understanding of these structures is important in their role as antigens and as candidate targets for vaccines. . The glycan database .

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

NOVEMBER 30, 2023

coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. The Absolute Antibody team was available to discuss custom services, as well as the company’s comprehensive antibody reagent catalogue.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

FEBRUARY 15, 2023

This has been possible with the advent of multiple IO-based therapies including anti-tumour antibodies, immunostimulatory cytokines, co-inhibitory antagonists, co-stimulatory agonists, immunological cell death inducers, and therapeutic cancer vaccines. A brief history of vaccines and vaccination. Front Immunol. 2017) 8:829.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

FEBRUARY 8, 2023

This approach, however, can be time-consuming, laborious, and require expensive reagents, including serotype-specific antibodies. Methods such as ELISA/qPCR offer well-established, sensitive, and specific analyses that can measure capsid titre versus genome titre, quantifying empty and full capsids 3.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

The Pharma Data

JANUARY 21, 2021

He’ll also issue executive orders that aim to ramp up the production and distribution of COVID-19 tests and vaccines, make schools and travel safer, and help states fight the spread of coronavirus. The new plan also steers more money to states, which have complained they need more funding to test and vaccinate residents.

Vaccination 52

Vaccination Vaccine Antibody Reagent 52